Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), α-1-antichymotrypsin (ACT), and the PSA-ACT complex

Prostate

Volumn 56, Issue 2, 2003, Pages 131-141

  Wan, X Steven ^a,c   Xu, Y Anne ^b   Ware, Jeffrey H ^a   Kennedy, Ann R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Exzyme Inc   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

1 antichymotrypsin (ACT); Enzyme linked immunosorbant assay (ELISA); Prostate specific antigen (PSA); PSA ACT complex

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER CYTODIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; WESTERN BLOTTING; ANIMAL; HUMAN; HYBRIDOMA; IMMUNOLOGY; MALE; METHODOLOGY; NON-PROGRAMMATIC; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

NON-PROGRAMMATIC;

ALPHA 1-ANTICHYMOTRYPSIN; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYBRIDOMAS; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0042809892     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10247     Document Type: Article

References (43)

1. Oesterling JE. Prostate-specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
2. Ablin RJ, Soanes VVA, Bronson P, Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertility 1970;22:573-574.
3. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: A new potential marker for prostatic cancer. Prostate 1981;2:89-96.
4. Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J Forensic Sci 1978;23:106-115.
5. Lilja H, Cockett ATK, Abrahamsson P-A. Prostate specific antigen predominantly forms a complex with alpha-1-antichymotrypsin in blood. Cancer Supplement 1992;70:230-234.
6. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903.
7. Watt KWK, Lee P-J, M'Timkulu T, Chan W-P, Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
8. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela LA, Nishiura T, Murphy GP, Chu TM. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40:4658-4662.
9. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
10. Turkes A, Nott JP, Griffiths K. Prostate-specific antigen: Problems in analysis. Eur J Cancer 1991;27:650-652.
11. Wu JT. Assay for prostate specific antigen (PSA): Problems and possible solutions. J Clin Lab Anal 1994;8:51-62.
12. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
13. Lilja H, Christensson A, Dahlen U, Matikainen M-T, Nilsson O, Pettersson K, Lougren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-1625.
14. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M-T, Cockett ATK, Abrahamsson P-A, Lilja H. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.
15. Oesterling JE, Jacobsen SJ, Klee GG, Petterson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovegren T, Lilja H. Free, complexed, and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-1095.
16. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-1120.
17. Luderer AL, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urol 1995;46:187-194.
18. Wu JT, Wilson L, Zhang P, Meikle AW, Stephenson R. Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 1995;9:15-24.
19. Wu JT, Zhang P, Liu GH, Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 1998;12:14-19.
20. Espana F, Martinez M, Sanchez-Cuenca J, Vera CD, Estelles A, Jimenez-Cruz JF. Prostate-specific antigen and its complexes with alpha-1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol 1996;30:512-518.
21. Armbruster DA. Prostate-specific antigen: Biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-195.
22. Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997;43:1588-1594.
23. Michel S, Deleage G, Charrier JP, Passagot J, Battail-Poirot N, Sibai G, Jolivet M, Jolivet-Reynaud C. Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling. Clin Chem 1999;45:638-650.
24. Nilsson O, Andersson I, Peter A, Karlsson B. Characterization of antibodies to prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):43-51.
25. Leinonen J, Zhang WM, Paus E, Stenman UH. Reactivity of 77 antibodies to prostate-specific antigen with isoenzymes and complexes of prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):28-34.
26. Black MH, Grass CL, Leinonen J, Stenman UH, Diamandis EP. Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. Clin Chem 1999;45:347-354.
27. Nixon RG, Meyer GE, Blase AB, Gold MH, Brawer MK. Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 1998;160:420-425.
28. Matsumoto K, Konishi N, Hiasa Y, Kimura E, Takahashi Y, Shinohara K, Samori T. A highly sensitive enzyme-linked immunoassay for serum free prostate specific antigen (f-PSA). Clinica Chimica Acta 1999;281:57-69.
29. Stenman UH, Paus E, Allard WJ, Andersson I, Andres C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Bormer OP, Davis G, Dowell B, Grauer LS, Jette DC, Karlsson B, Kreutz FT, van der Kwast TM, Lauren L, Leinimaa M, Leinonen J, Lilja H, Linton HJ, Nap M, Hilgers Jea. Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):1-12.
30. Wang TJ, Linton HJ, Payne J, Rittenhouse HG, Chan DW, Partin AW, Wolfert RL, Kuus-Reichel K. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. Hybridoma 1999;18:535-541.
31. Chen Z, Chen H, Stamey TA. Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to alpha-1-antichymotrypsin. J Urol 1998;160:870-875.
32. Harlow E, Lane D. Antibodies: A laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1988.
33. Wan XS, Koch CJ, Lord EM, Manzone H, Billings PC, Donahue JJ, Odell CS, Miller JH, Schmidt NA, Kennedy AR. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor. J Immunol Methods 1995;180:117-130.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
35. Hara M, Inorre T, Fukuyama T. Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. (Japanese). Jap J Legal Med 1971;25:322-324.
36. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991;353:576-578.
37. Schechter NM, Sprows JL, Schoenberger OL, Lazarus GS, Cooperman BS, Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem 1989;264:21308-21315.
38. Jette DC, Kreutz FT, Suresh MR. Relative affinity and specificity of monoclonal antibodies against prostate-specific antigen. Tumour Biol 1999;20(Suppl 1):24-27.
39. Belanger A, Rong PM, Liu S, Lavoie L, Labrie F. Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin Investigative Med 1993;16:409-414.
40. Corey E, Wegner SK, Stray JE, Corey MJ, Arfman EW, Lange PH, Vessella RL. Characterization of 10 new monoclonal antibodies against prostate-specific antigen by analysis of affinity, specificity and function in sandwich assays. Int J Cancer 1997;71:1019-1028.
41. Allard WJ, Zhou Z, Yeung KK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 1998;44:1216-1623.
42. Matsumoto K, Konishi N, Samori T, Kimura E, Doi M, Kato S, Yuki Y. ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen-assay-specific for complexed prostate-specific antigen. J Immunol Methods 2000;234:99-106.
43. Zhou Z, Armstrong EG, Belenky A, Freeman JV, Yeung KK. Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody. J Clin Lab Analysis 1998;12:242-249.